Telomir Pharmaceuticals (Telomir Pharmaceuticals) Construction In Progress : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Construction In Progress?

Telomir Pharmaceuticals Construction In Progress Historical Data

The historical data trend for Telomir Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Construction In Progress Chart

Telomir Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Construction In Progress

Telomir Pharmaceuticals Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial				-	-	-	-	-

Telomir Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines

From GuruFocus

UPDATE -- Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

By GlobeNewswire • 03-29-2024